ACE-031 and MK-2866 Interaction: Monitor | Peptide Database

ACE-031 bone density research extends the compound’s primary myostatin-inhibition biology into skeletal biology through the shared ActRIIB ligand system that regulates both muscle and bone remodelling. Myostatin’s direct anti-osteoblastic and pro-osteoclastic effects — suppressing RUNX2-driven differentiation and increasing RANKL:OPG ratio — are antagonised by ACE-031’s ligand trapping, while activin A neutralisation addresses the additional bone-resorbing signal elevated in multiple disease contexts. Preclinical evidence in healthy animals and OVX osteoporosis models demonstrates increased BV/TV, cortical thickness and bone strength with ActRIIB-Fc treatment. Disease models where muscle and bone pathology co-occur (DMD, ALS, cancer cachexia) provide research contexts for simultaneous dual-compartment endpoint assessment. Micro-CT structural parameters, bone turnover biomarkers, histomorphometric cellular endpoints and biomechanical strength testing together constitute the standard toolkit for characterising ACE-031’s skeletal effects comprehensively. Research Use Only — UK Regulatory Notice: ACE-031 is available for purchase in the United Kingdom for research and laboratory purposes only. It is not approved for human therapeutic use, is not a licensed medicinal product, and is not intended for use in clinical practice, human self-administration or veterinary treatment without appropriate regulatory authorisation. All research applications must comply with applicable UK legislation and institutional ethical oversight requirements. 🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified ACE-031 for research and laboratory use. View UK stock → William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

Join others researching ACE-031 — share findings, ask questions, and learn from real experiences ACE-031 is a soluble form of the activin type IIB receptor (ActRIIB) fused to an IgG1 Fc domain. It functions as a decoy receptor, binding and neutralizing myostatin and other TGF-beta superfamily members that normally limit muscle growth. Originally developed by Acceleron Pharma for Duchenne muscular dystrophy (DMD), ACE-031 reached Phase 2 clinical trials before development was halted due to vascular side effects including nosebleeds and telangiectasia. In healthy volunteers, a single dose produced significant increases in lean mass and reductions in fat mass within 29 days. ACE-031 acts as a ligand trap for members of the TGF-beta superfamily. By mimicking the extracellular domain of the ActRIIB receptor, it intercepts myostatin (GDF-8), activin A, activin B, and GDF-11 before they can bind cell-surface receptors and activate Smad2/3 signaling. Blocking this pathway removes the natural brake on muscle protein synthesis and satellite cell proliferation, resulting in rapid skeletal muscle hypertrophy. The Fc fusion domain extends circulating half-life through FcRn-mediated recycling and provides bivalent ligand binding.